The dynamics of respiratory changes on the background of inhalation treatment with tauractant in patients in the post-covid period

Introduction. Pulmonary surfactant is a key component of the respiratory system that ensures the stability of the alveoli by reducing surface tension, preventing collapse of the respiratory tract and protecting against infections. Its dysfunction is observed in severe respiratory diseases, including COVID-19, ARDS, pneumonia, COPD and bronchial asthma. Of particular interest is the inhalation use of exogenous forms of surfactant not only in acute COVID-19, but also in the post-covid period.

Aim. The aim of the study is to evaluate the effectiveness of a course of inhalation of tauractant emulsion (Surfactant-BL) through a nebulizer in patients with COVID-associated pneumonia with persistent ventilation disorders after 3 months of therapy in the post-covid period.

Materials and methods: The study included 60 patients with COVID-associated pneumonia with confirmed violations of lung ventilation and pronounced residual changes in lung tissue, who were randomly divided into 2 groups – the main group (n = 30) and the comparison group (n = 30). The main group, in addition to the standard therapy for post-covid syndrome, received a course of inhalation with Surfactant-BL twice a day for 7 days. All patients underwent a comprehensive study of respiratory function (spirography, bodyplethysmography and diffusion test) at the stage of inclusion in the study and after 3 months.

Results. In the main group, significant positive dynamics in FEV1, FEV1/FVC, FRC, and TLC were revealed, while the diffusion capacity DLCO of the lungs did not significantly change.

Conclusion. In this study, the effectiveness of the use of an exogenous surfactant in the post-pregnancy period was demonstrated. It is advisable to continue conducting studies using more numerous groups of patients to determine clear criteria for the use of inhaled surfactant therapy in the post-covid period.

1. Epaud R, Ikegami M, Whitsett JA, Jobe AH, Weaver TE, Akinbi HT. Surfactant protein B inhibits endotoxin-induced lung inflammation. Am J Respir Cell Mol Biol. 2003;28(3):373–378. https://doi.org/10.1165/rcmb.2002-0071OC.

2. Milad N, Morissette MC. Revisiting the role of pulmonary surfactant in chronic inflammatory lung diseases and environmental exposure. Eur Respir Rev. 2021;30(162):210077. https://doi.org/10.1183/16000617.0077-2021.

3. Herman L, De Smedt SC, Raemdonck K. Pulmonary surfactant as a versatile biomaterial to fight COVID-19. J Control Release. 2022;342:170–188. https://doi.org/10.1016/j.jconrel.2021.11.023.

4. Rosenberg OA. Pulmonary Surfactant Preparations and Surfactant Therapy for ARDS in Surgical Intensive Care (a Literature Review). Creative Surgery and Oncology. 2019;9(1):50–65. (In Russ.) https://doi.org/10.24060/2076-3093-2019-9-1-50-65.

5. Piva S, DiBlasi RM, Slee AE, Jobe AH, Roccaro AM, Filippini M et al. Surfactant therapy for COVID-19 related ARDS: a retrospective casecontrol pilot study. Respir Res. 2021;22(1):20. https://doi.org/10.1186/s12931-020-01603-w.

6. Meng SS, Chang W, Lu ZH, Xie JF, Qiu HB, Yang Y, Guo FM. Effect of surfactant administration on outcomes of adult patients in acute respiratory distress syndrome: a meta-analysis of randomized controlled trials. BMC Pulm Med. 2019;19(1):9. https://doi.org/10.1186/s12890-018-0761-y.

7. Akella A, Deshpande SB. Pulmonary surfactants and their role in pathophysiology of lung disorders. Indian J Exp Biol. 2013;51(1):5–22. Режим доступа: https://pubmed.ncbi.nlm.nih.gov/23441475.

8. Tatarintseva MP, Batishcheva TL, Demidkov IN, Aroyan AR, Miletskiy AV. Complex treatment of destructive pulmonary tuberculosis using inhaled tauractant therapy. Meditsinskiy Sovet. 2023;17(20):100–104. (In Russ.) https://doi.org/10.21518/ms2023-372.

9. Volchkova EV, Alexandrovich YuS, Titova ON, Kuzubova NA, Volchkov VA, Piskunov DP et al. Pulmonary surfactant in the complex treatment of severe pneumonia associated with COVID-19. Efficacy markers. RMJ. Medical Review. 2022;6(7):352–359. (In Russ.) https://doi.org/10.32364/2587-6821-2022-6-7-352-359.

10. Busani S, Dall’Ara L, Tonelli R, Clini E, Munari E, Venturelli S et al. Surfactant replacement might help recovery of low-compliance lung in severe COVID-19 pneumonia. Ther Adv Respir Dis. 2020;14:1753466620951043. https://doi.org/10.1177/1753466620951043.

11. Окладников СМ, Никитина СЮ (ред.). Здравоохранение в России. 2023: статистический сборник. М.: Росстат; 2023. 181 с. Режим доступа: http://ssl.rosstat.gov.ru/storage/mediabank/Zdravoohran-2023.pdf.

12. Baimukhambetova DV, Gorina AO, Rumyantsev MA, Shikhaleva AA, El-Taravi YaA, Bondarenko ED et al. Post-covid condition in adults and children. Pulmonologiya. 2021;31(5):562–570. (In Russ.) https://doi.org/10.18093/0869-0189-2021-31-5-562-570.

13. Antoniou KM, Vasarmidi E, Russell AM, Andrejak C, Crestani B, Delcroix M et al. European Respiratory Society statement on long COVID follow-up. Eur Respir J. 2022;60(2):2102174. https://doi.org/10.1183/13993003.02174-2021.

14. Avdeev SN, Trushenko NV, Chikina SY, Tsareva NA, Merzhoeva ZM, Yaroshetskiy AI et al. Beneficial effects of inhaled surfactant in patients with COVID-19-associated acute respiratory distress syndrome. Respir Med. 2021;185:106489. https://doi.org/10.1016/j.rmed.2021.106489.

15. Bautin AE, Aptekar VV, Lapshin KV, Semenov AP, Mineeva EV, Anokhina NA et al. Exogenous surfactant in the treatment of severe pneumonia caused by the SARS-CoV-2 virus. Translational Medicine. 2020;7(6):55–64 (In Russ.). https://doi.org/10.18705/2311-4495-2020-7-6-55-64.

16. Heching M, Lev S, Shitenberg D, Dicker D, Kramer MR. Surfactant for the Treatment of ARDS in a Patient With COVID-19. Chest. 2021;160(1):e9–e12. https://doi.org/10.1016/j.chest.2021.01.028.

17. Averyanov AV, Klypa TV, Balionis OI, Bychinin MV, Cherniak AV, Troitskiy AV et al. Inhaled surfactant in patients with covid-19 who took high-flow oxygen: the results of a retrospective analysis. Meditsinskiy Sovet. 2020;(17):75–80. (In Russ.) https://doi.org/10.21518/2079-701X2020-17-75-80.

18. Авдеев СН, Адамян ЛВ, Алексеева ЕИ, Багненко СФ, Баранов АА, Баранова НН и др. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 15 (22.02.2022)». Режим доступа: https://tub-spb.ru/wpcontent/uploads/2022/06/profilaktika-diagnostika-i-lechenie-novojkoronavirusnoj-infekczii-covid-19.-versiya-15-22.02.2022.pdf.

19. Каменева МЮ, Черняк АВ, Айсанов ЗР, Перельман ЮМ, Приходько АГ, Чушкин МИ и др. Спирометрия: методические рекомендации. М.; 2023. 64 с. Режим доступа: https://spulmo.ru/upload/kr/Spirometria_2023.pdf.

20. Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019;200(8):e70–e88. https://doi.org/10.1164/rccm.201908-1590ST.

21. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F et al. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26(3):511–522. https://doi.org/10.1183/09031936.05.00035005.

22. Graham BL, Brusasco V, Burgos F, Cooper BG, Jensen R, Kendricket А et al. 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. Eur Respir J. 2017;49(1):1600016. https://doi.org/10.1183/13993003.00016-2016.

23. Aisanov ZR, Kalmanova EN, Kameneva MYu, Kiryukhina LD, Lukina OF, Naumenko JK et al. Recommendations of the Russian Respiratory Society on scientific research of the treatment system during the COVID-19 pandemic. Version 1.1. from 05.19.2020. Prakticheskaya Pulʹmonologiya. 2020;(1):104–106. (In Russ.) Available at: https://atmosphere-ph.ru/modules/Magazines/articles//pulmo/pp_1_2020_104.pdf.

24. Shapovalov KG, Lukyanov SА, Konnov VА, Rozenberg OА. Exogenous surfactant in the late respiratory phase of COVID-19. Tuberculosis and Lung Diseases. 2021;99(5):7–13. (In Russ.) https://doi.org/10.21292/2075-1230-2021-99-5-7-13.

25. Stulikova IYu, Tsvetkova AV, Koneva ES, Shapovalenko TV. Clinical case of nebulized surfactant therapy for severe COVID-19-associated pneumonia at the 2nd stage of rehabilitation treatment. Meditsinskiy Sovet. 2021;(16):78–84. (In Russ.) https://doi.org/10.21518/2079-701X2021-16-78-84.

26. Dudchenko LSh, Belyaeva SN, Solovyova EA, Kozhemyachenko EN. Pulmonary surfactant in rehabilitation of patients suffering COVIDassociated pneumonia. Herald of Physiotherapy and Health Resort Therapy. 2023;29(2):10–12. (In Russ.) Available at: https://cyberleninka.ru/article/n/preparat-legochnogo-surfaktanta-v-reabilitatsii-bolnyhperenesshih-covid-assotsiirovannuyu-pnevmoniyu.